Broadcasting News

Joo Jin-mo to Become a Father After 7 Years of Marriage… Wife Min Hye-yeon Is Pregnant

Welcomes First Child with Wife, a Doctor 11 Years His Junior Agency: “She is in the early stages of pregnancy, so we are proceeding with caution”

YUN GI BACK
2026-11-14 13:35:40
[Edaily Reporter YUN GI BACK ] Actor Joo Jin-mo is set to become a father seven years after his marriage. Following reports that his wife, family medicine specialist Min Hye-yeon, is pregnant, his agency officially confirmed the news and asked for congratulations and support.
Joo Jin-mo (Photo: E-Daily DB)

On the 14th, Joo Jin-mo’s agency, KHS Agency, addressed the news of Min Hye-yeon’s pregnancy, stating, “It is true that she is pregnant.” They added, “However, as it is still early in the pregnancy and a delicate stage, it is difficult to provide specific details. As this is happy news, we ask for your blessings and support.”
Joo Jin-mo and Min Hye-yeon were married in June 2019. Born in 1974, Joo Jin-mo is 11 years older than Min Hye-yeon, who was born in 1985; Min Hye-yeon is a physician who graduated from Seoul National University College of Medicine. The couple is expecting their first child seven years after their marriage.
Joo Jin-mo made his acting debut in the 1999 film *Dance Dance* and has since appeared in numerous works, including *Musa*, *Beauty Is a Pain*, and *Ssanghwa-jeom*. He also gained popularity through the drama *Empress Ki*.
After taking a break from acting following the 2019 drama “Big Issue,” he appeared on TV Chosun’s “Heo Young-man’s White Rice Journey” in 2024 and held a fan meeting in Japan last year to meet with fans.

Economy

Corporation

IT·Science

Economy

“Investment Dried Up, but a 140 Billion Windfall”… The British Fintech Company Chosen by Uber [Economy with the EU]

As the volume of fintech investment in the UK has fallen to its lowest level in 10 years, Griffin—a startup specializing in banking infrastructure and known as a financial partner of Uber—has successf…
2026-11-14 11:16:03

Corporation

Rookie Baropharm and Embattled Moalife Plus Face Paradoxical Volatility as GC Genome Anchors the Market [K-Bio Pulse]

Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
2026-11-14 12:47:03

IT·Science

“The Era of 1.5 Million Robots”… The Korean Company JP Morgan Has Singled Out

A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…
2026-11-14 08:36:21